首页> 外文期刊>Biological research: BR >Ultrastructural changes of erythrocytes in whole blood after exposure to prospective in silico -designed anticancer agents: a qualitative case study
【24h】

Ultrastructural changes of erythrocytes in whole blood after exposure to prospective in silico -designed anticancer agents: a qualitative case study

机译:暴露于计算机设计的前瞻性抗癌药后全血中红细胞的超微结构变化:定性案例研究

获取原文
       

摘要

Novel, in silico-designed anticancer compounds were synthesized in our laboratory namely, 2-ethyl-3-O-sulphamoyl-estra-1,3,5(10),15-tetraen-17-ol (ESE-15-ol) and 2-ethyl-3-O-sulphamoyl-estra-1,3,5(10)16-tetraene (ESE-16). These compounds were designed to have improved bioavailability when compared to their source compound, 2-methoxyestradiol. This theoretically would be due to their increased binding affinity to carbonic anhydrase II, present in erythrocytes. Since the novel compounds under investigation are proposed to be transported within erythrocytes bound to carbonic anhydrase II, the morphological effect which they may exert on whole blood and erythrocytes is of great significance. A secondary outcome included revision of previously reported procedures for the handling of the whole blood sample. The purpose of this study was twofold. Firstly, the ultrastructural morphology of a healthy female’s erythrocytes was examined via scanning electron microscopy (SEM) after exposure to the newly in silico-designed compounds. Morphology of erythrocytes following exposure to ESE-15-ol and ESE-16 for 3?minutes and 24?hours at 22°C were described with the use of SEM. The haemolytic activity of the compounds after 24?hours exposure were also determined with the ex vivo haemolysis assay. Secondly, storage conditions of the whole blood sample were investigated by determining morphological changes after a 24?hour storage period at 22°C and 37°C. No significant morphological changes were observed in the erythrocyte morphology after exposure to the novel anticancer compounds. Storage of the whole blood samples at 37°C for 24?hours resulted in visible morphological stress in the erythrocytes. Erythrocytes incubated at 22°C for 24?hours showed no structural deformity or distress. From this research the optimal temperature for ex vivo exposure of whole blood samples to ESE-15-ol and ESE-16 for 24?hours was determined to be 22°C. Data from this study revealed the potential of these compounds to be applied to ex vivo study techniques, since no damage occurred to erythrocytes ultrastructure under these conditions. As no structural changes were observed in erythrocytes exposed to ESE-15-ol and ESE-16, further ex vivo experiments will be conducted into the potential effects of these compounds on whole blood. Optimal incubation conditions up to 24?hours for whole blood were established as a secondary outcome.
机译:在我们的实验室中合成了计算机设计的新型抗癌化合物,即2-乙基-3-O-磺酰基-estra-1,3,5(10),15-丁烯-17-ol(ESE-15-ol)和2-乙基-3-O-磺酰基-雌激素-1,3,5(10)16-四烯(ESE-16)。与它们的来源化合物2-甲氧基雌二醇相比,这些化合物被设计为具有更高的生物利用度。从理论上讲,这是由于它们与存在于红细胞中的碳酸酐酶II的结合亲和力增加。由于提议研究中的新化合物在与碳酸酐酶II结合的红细胞内运输,因此它们可能对全血和红细胞产生的形态学效应具有重要意义。次要结果包括修订先前报告的全血样品处理程序。这项研究的目的是双重的。首先,健康的女性红细胞的超微结构形态在暴露于新的计算机设计的化合物后通过扫描电子显微镜(SEM)进行了检查。利用SEM描述了在22℃下暴露于ESE-15-ol和ESE-16 3分钟和24小时后的红细胞形态。还通过离体溶血测定法测定了化合物暴露24小时后的溶血活性。其次,通过确定在22℃和37℃下24小时的储存时间后的形态变化来研究全血样品的储存条件。暴露于新型抗癌化合物后,在红细胞形态上未观察到明显的形态变化。全血样品在37°C下储存24小时会导致红细胞出现明显的形态学应激。在22°C下孵育24小时的红细胞未显示任何结构变形或不适。根据这项研究,确定全血样品在ESE-15-ol和ESE-16体外暴露24小时的最佳温度为22°C。这项研究的数据揭示了这些化合物在体外研究技术中应用的潜力,因为在这些条件下不会对红细胞超微结构造成损害。由于在暴露于ESE-15-ol和ESE-16的红细胞中未观察到结构变化,因此将对这些化合物对全血的潜在作用进行进一步的离体实验。次要结果是确定全血长达24小时的最佳孵育条件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号